Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change
26-06-17	0.0530 €	0.00%
26-06-16	0.0530 €	0.00%
26-06-15	0.0530 €	0.00%
26-06-12	0.0530 €	0.00%
26-06-11	0.0530 €	-0.93%

End-of-day quote Deutsche Boerse AG

More quotes

End-of-day quote Deutsche Boerse AG Other stock markets 2026-06-15			5-day change	1st Jan Change
0.0530 ^EUR	0.00%		-0.93%	+301.52%

Market Cap	144K 165K 133K 125K 234K 15.59M 235K 1.58M 614K 7.68M 621K 607K 26.62M	P/E 2021	-3.89x	P/E 2022	-53x
Enterprise Value	9.87M 11.32M 9.1M 8.56M 16.01M 1.07B 16.12M 108M 42.03M 526M 42.51M 41.6M 1.82B	EV / Sales 2021	14.1x	EV / Sales 2022	1.22x
Free-Float	90.91%	Yield 2021 *	-	Yield 2022	-

1 week	-0.93%
Current month	-6.19%
1 month	-8.62%
3 months	-24.50%
6 months	+341.67%
Current year	+301.52%

1 week	0.05	0.05
1 month	0.05	0.14
Current year	0.01	0.23
1 year	0	0.23
3 years	0	8.52
5 years	0	20.3
10 years	0	36.78

Manager	Title	Age	Since
Tilmann Bur CEO	Chief Executive Officer	62	2023-08-31
Sebastian Werner DFI	Director of Finance/CFO	-	2022-05-31

Paion AG Stock

Stocks

PA8K

DE000A3E5EG5

Biotechnology & Medical Research

Valuation: Paion AG

Chart: Paion AG

Latest news : Paion AG

Press Releases: Paion AG

News in other languages: Paion AG

Quotes and Performance

Course Extremes

Managers and Directors: Paion AG

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Director	Title	Age	Since
Karin Louise Dorrepaal BRD	Director/Board Member	65	2012-09-30
Hans Tanner BRD	Director/Board Member	75	2017-05-31
Markus Guilherme Dieken BRD	Director/Board Member	-	2019-05-21

Date	Insider	Type	Main position	Quantity	% Market Cap.
22-12-26	Gregor Siebert	Buy	Director	1,121	0.0016%
21-01-11	James Phillips	Buy	Chief Executive Officer	8,500	0.0127%
20-06-07	James Phillips	Buy	Chief Executive Officer	13,158	0.0202%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PAION AG	0.00%	-0.93%	+381.82%	-99.32%	438K
LONZA GROUP AG	-0.34%	-0.08%	-12.15%	-10.46%	43.44B
REVOLUTION MEDICINES, INC.	+1.42%	+7.56%	+301.98%	+525.04%	33.54B
IQVIA HOLDINGS INC.	-3.20%	-9.46%	+6.03%	-23.73%	28.48B
BEONE MEDICINES AG	+2.61%	+3.38%	+6.45%	+40.46%	29.2B
CELLTRION, INC.	-0.57%	+3.77%	+12.66%	+20.42%	25.34B
ASCENDIS PHARMA A/S	+0.37%	+8.14%	-	-	14.36B
MEDPACE HOLDINGS, INC.	+0.15%	-4.52%	+49.86%	+101.34%	13.05B
EUROFINS SCIENTIFIC SE	+0.54%	-2.27%	+3.93%	+4.80%	12.67B
IONIS PHARMACEUTICALS, INC.	+0.36%	+0.61%	+100.68%	+80.84%	12.28B
Average	+0.11%	+0.54%	+94.58%	+71.04%	21.24B
Weighted average by Cap.	+0.09%	+0.79%	+61.71%	+103.81%

	2021	2022
Net sales	7.13M 8.18M 6.57M 6.18M 11.56M 771M 11.64M 78.18M 30.36M 380M 30.71M 30.05M 1.32B	33.25M 38.16M 30.65M 28.83M 53.93M 3.6B 54.31M 365M 142M 1.77B 143M 140M 6.14B
Net income	-21.79M -25M -20.08M -18.89M -35.34M -2.36B -35.59M -239M -92.79M -1.16B -93.85M -91.84M -4.03B	-579K -665K -534K -502K -939K -62.63M -946K -6.35M -2.47M -30.86M -2.49M -2.44M -107M
Net Debt	13.77M 15.8M 12.69M 11.94M 22.34M 1.49B 22.49M 151M 58.65M 734M 59.32M 58.05M 2.54B	9.72M 11.16M 8.96M 8.43M 15.77M 1.05B 15.88M 107M 41.41M 518M 41.89M 40.99M 1.8B